2.4.0.8128 - Disclosure - Commitments and Contingencies - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]2false 4us-gaap_CostOfReimbursableExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7500075000USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Estimates reimbursable past patent expenses3false 4bpth_AccruedPatentExpenseCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2500025000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Patent Expense, CurrentNo definition available.false2Patent expense per quarter4false 4bpth_AccruedLiabilitiesRelatedPartyCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3705037050USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities Related Party CurrentNo definition available.false2Accrued expense - related party5false 4us-gaap_OtherInventoryus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsedefinitionGuidance1truefalsefalse279180279180USD$falsefalsefalse2truefalsefalse195000195000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 false2Other inventory, gross6false 4bpth_DrugProductTestingAgreementConsiderationToBePaidInStagesbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse340000340000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents consideration to be paid in various stages with respect to agreement with its drug product manufacturer for testing.No definition available.false2Drug Product Testing Agreement Consideration To Be Paid In Stages7false 4bpth_DrugProductEstimatedCostbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse165000165000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryDrug Product Estimated CostNo definition available.false2Drug Product Estimated Cost8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$PAsOn06_30_2013_PatentedTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalsePatented Technologyus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentedTechnologyMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Patented Technology9true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]10false 4bpth_AccruedLiabilitiesRelatedPartyCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1001710017USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities Related Party CurrentNo definition available.false2Accrued expense - related party11false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse4false USDtruefalse$PAsOn06_30_2013_TechnologyLicensesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseTechnology Licensesus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_TechnologyLicensesMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Technology Licenses12true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]13false 4us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5000050000USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(1),(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 1, 5 -Article 9 false2Accounts payable and accrued liabilitiesfalseCommitments and Contingencies - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/CommitmentsAndContingenciesAdditionalInformationDetail213